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Abstract
Extranodal natural killer/T-cell lymphoma (ENKTL), nasal type, is a rare form of non-Hodgkin lymphoma. Treatment
of ENKTL primarily relies on radiation; thus, proper delineation of target volumes is critical. Currently, the ideal
modalities for delineation of gross tumor volume for ENKTL are unknown. We describe three consecutive cases of
localized ENKTL that presented to the Nova Scotia Cancer Centre in Halifax, Nova Scotia. All patients had a
planning CT and MRI as well as a planning FDG-PET/CT in the radiotherapy treatment position, wearing
immobilization masks. All patients received radiation alone. In two patients, PET/CT changed not only the stage,
but also the target volume requiring treatment. The third patient was unable to tolerate an MRI, but was able to
undergo PET/CT, which improved the accuracy of the target volume. PET/CT aided the staging of and radiotherapy
planning for our patients and appears to be a promising tool in the treatment of ENKTL.
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Background
Extranodal natural killer/T-cell lymphoma (ENKTL),
nasal type, has been known by various names: malignant
midline reticulosis, polymorphic reticulosis, lethal mid-
line granuloma, and angiocentric immunoproliferative
lesion [1]. ENKTL often presents as a nasal mass, caus-
ing obstruction or bleeding and may elicit symptoms
similar to that of a nasal sinus infection. The sites most
commonly involved include the nasal cavity, paranasal
sinuses, nasopharynx, hypopharynx, larynx, and tonsils
[2].
ENKTL accounts for < 1% of all non-Hodgkin lym-
phomas in North America, making it a rare diagnosis in
this population [3]. The ENKTL subtype is more com-
mon in Asia where it constitutes 6-8% of non-Hodgkin
lymphomas [3,4]. The median age of diagnosis is 50
years and male-to-female sex ratio is approximately 3:1
[4]. The most common immunophenotype is CD3
-,
CD3ε
+,C D 5 6
+, Epstein-Barr virus-encoded early small
RNA (EBER)
+ [4].
Although there is no standard treatment for ENKTL,
radiotherapy constitutes a significant component of its
management [2,5]. This tumor type does not usually
respond to anthracycline-based chemotherapy [5,6];
however, recent Phase I and Phase II trials have sug-
gested that concurrent chemoradiotherapy using nonan-
thracycline-based drugs may improve outcomes in stage
IE and IIE disease [6,7]. Chemotherapy post-radiation
may also be beneficial [8]. Because treatment relies pri-
marily on radiotherapy, delineating the proper target
volumes for irradiation is critical.
The use of inadequately accurate imaging for radiation
therapy volume delineation may lead to missed tumor
or the irradiation of excessive volumes of normal tissue.
Currently, the ideal modalities for delineation of the tar-
get volume for ENKTL are unknown. Computed tomo-
graphy (CT) and magnetic resonance imaging (MRI) are
most commonly used [2]. Positron emission tomography
(PET)/CT appears to be a promising tool for the staging
of and radiotherapy planning for ENKTL [9-11]. ENKTL
lesions are fluorine-18 fluorodeoxyglucose (
18F-FDG)
avid [9,10], suggesting that PET/CT may be useful in
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Despite its promise, the utility of PET/CT in the man-
agement of ENKTL is not well described.
We present three cases of localized ENKTL and out-
line the utility of PET/CT in the staging and radiother-
apy planning processes.
Case Presentations
Three Caucasian patients with localized ENKTL pre-
sented to the Nova Scotia Cancer Centre in Halifax,
Nova Scotia, Canada. As per institutional intensity
modulated radiotherapy (IMRT) protocol, all patients
had a planning CT and MRI.
These patients also underwent FDG-PET/CT in the
radiotherapy treatment position, wearing immobilization
masks, to help assign stage and to aid in the selection of
target volumes for radiotherapy. Sixty minutes following
injection with 370 MBq of
18FDG, imaging was per-
formed from skull base to proximal thighs on a dedi-
cated PET/CT scanner (GE Discovery STE16, GE
HealthCare, Milwaukee).
The attending radiation oncologist delineated the
gross tumor volume (GTV) based on the anatomical
extent of the tumor, as determined by physical examina-
tion, as well as the planning CT and MRI. The MRI was
primarily used to guide the precision of delineation. The
main purpose of the PET/CT was to determine which
nodes were suspicious for involvement and to guide the
delineation of the extranodal component of the GTV.
Standardized uptake value (SUV) thresholds were not
used for tumor delineation. All patients received radio-
therapy alone.
Case 1
A 61-year-old woman presented with a yearlong history
of chronic sinusitis and a painful ulcerative lesion invol-
ving the soft palate. A biopsy of the lesion revealed
ENKTL (CD3
+,C D 5 6
+,C D 4
+,C D 8
+,E B E R
+). Lactate
dehydrogenase (LDH) levels were normal. Eastern coop-
erative oncology group (ECOG) performance status was
0. Physical examination and flexible fiberoptic nasolar-
yngoscopy were performed and demonstrated a tumor
involving the entire soft palate, bilateral palatine tonsil-
lar areas, and nasopharynx. Body CT, bone marrow
aspirate, and bone biopsy revealed no distant dissemina-
tion. A diagnostic MRI of the neck was contraindicated
as a result of the patient’s implanted bladder stimulator
a n da nM R Io ft h eh e a du s i n gah e a dc o i lw a sp e r -
formed instead. The PET/CT revealed involvement of
the lingual tonsils and bilateral subcentimeter regional
lymph nodes, which were not appreciated clinically or
on previous imaging (Figures 1 &2).
The SUVmax of the primary lesion in the palate was
18.9 and was contiguous with the palatine tonsils. The
lingual tonsils demonstrated clearly abnormal uptake
and given their proximity to the primary lesion and
being part of Waldeyer’s Ring, it was determined that
they were clinically involved by ENKTL. The SUVmax
of the lymph nodes was 3.5. Although uptake in the
nodes was less than that in the primary lesion, it would
be underestimated given their small size. The uptake
was clearly abnormally elevated and the lymph nodes
were deemed likely involved.
The tumor was classified as Stage IIAE and the
planned treatment volume was increased to include the
lingual tonsils and regional lymph nodes. The prescribed
dose to the GTV was 60 Gy/30 fractions over five
weeks, six fractions per week, with one twice-a-day
treatment per week. The prescribed dose to the elective
nodal volume was 48 Gy/30 fractions, using a two level
simultaneous integrated boost technique. The patient
has been followed for 25 months without recurrence.
Case 2
An 82-year-old man with early dementia and moderate
cognitive impairment presented with an enlarging mass
arising from the lateral aspect of the superior nasal cav-
ity, invading the medial canthus of the right eye. Biopsy
of the mass revealed ENKTL (CD3
+, CD56
+, CD4
+, CD8
+, EBER
+). LDH levels were normal. ECOG performance
status was 2. Physical examination and flexible fiberoptic
nasolaryngoscopy revealed a 2 cm mass on the lateral
aspect of the right, superior nose. The tumor did not
involve the posterior nasal cavity or the pharynx. MRI
was attempted, but was not tolerated. The patient was
able to tolerate a PET/CT (Figures 3 &4). The PET/CT
was used to outline the target volume. SUVmax of the
lesion was 4.5 and the tumor was Stage IAE. The treat-
ment plan was intended to be palliative and consisted of
stereotactic IMRT, 42.5 Gy/10 fractions, using a reloca-
table head-frame. At the time of manuscript submission,
the patient was living and had no evidence of
recurrence.
Case 3
A 49-year-old man presented with a recurrent nasal
mass in 2008. Biopsy of this area showed ENKTL (CD3
+,C D 5 6
+,C D 4
+,C D 8
+,E B E R
+). LDH was normal.
ECOG performance status was 1. In 1999, the patient
was diagnosed with Mantle cell lymphoma localized to
the nasal cavity, which was treated with 35 Gy/20 frac-
tions, using three-dimensional conformal radiotherapy.
Re-analysis of the 1999 lymphoma revealed that it was
also ENKTL (not Mantle cell). The patient initially
declined treatment of the recurrence due to a lack of
symptoms. Thirteen months later the patient agreed to
re-irradiation after experiencing unilateral nasal obstruc-
tion, ocular edema, and an elevated LDH.
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trol, and the localized nature of the relapse led to the
choice of re-irradiation. The patient was counseled
regarding the potential risk of delayed normal tissue
injury from re-radiation. Both the attending hematolo-
gist and radiation oncologist were in favor of this
approach.
Clinically, the tumor was confined to the right max-
illary sinus, with no regional adenopathy. A planning
MRI showed enlarged regional lymph nodes and a
PET/CT revealed that these nodes were FDG-PET-
avid, changing the stage from IAE to IIAE (Figure 5).
SUVmax of the primary lesion was 24. Level II nodes
posterior to the submandibular glands were consid-
ered involved (SUV = 5) whereas involvement of the
submandibular nodes was intermediate (SUV = 2.5).
Given the proximity of the submandibular nodes to
the level II nodes and the intermediate level of uptake
on PET, our suspicion was that they were likely
involved and they were targeted to receive 54 Gy/30
fractions. Because of the low degree of PET avidity of
the level III nodes (SUV = 1.8) and a low level of sus-
picion of involvement, they were targeted to receive
only 40 Gy/30 fractions, as part of the elective nodal
volume.
The prescribed dose to the GTV was 54 Gy/30 frac-
tions over five weeks, six fractions per week, with one
twice-a-day treatment per week. The prescribed dose to
the elective nodal volume was 40 Gy/30 fractions, using
a two level simultaneous integrated boost technique.
Figure 1 CT (soft tissue windows and bone windows), MRI, and PET sagittal views. Lingular tonsillar involvement is visualized on the PET,
but was not detected using CT or MRI.
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stable disease.
Conclusions
In all three cases, PET/CT improved target and normal
tissue delineation. In Case 1, PET/CT revealed the
involvement of the lingual tonsils as well as bilateral
subcentimeter regional lymph nodes, which were not
appreciated on CT or MRI of the head. This finding
changed not only the stage, but also the target volume
requiring treatment. That is, without the PET/CT, part
of the patient’s tumor would not have been treated.
In Case 2, the patient was unable to tolerate an MRI.
As tumor in the nasal cavity can be difficult to distin-
guish from mucous on a CT scan, the PET/CT
improved the accuracy in outlining the target volume.
The PET/CT was useful in determining the extent of
extranodal involvement and increased the size of the
GTV to be treated, compared to physical examination
and the planning CT alone.
Figure 2 CT, MRI, and PET axial views. Involvement of the bilateral subcentimeter regional lymph nodes was appreciated on PET, but not on
CT or MRI.
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Page 4 of 8Finally, in Case 3, the MRI revealed enlarged lymph
nodes that were not initially thought to be involved in
the disease process, but were found to be enlarged by
tumor on PET/CT. This finding changed the tumor
stage as well as the treatment target volume.
As stated previously, radiotherapy plays an important
role in the management of ENKTL. However, the failure
rate for radiation alone is between 25% and 30% for
early stage disease; the presence of occult disease most
likely accounts for a portion of this failure rate [8]. In
order to address distant occult disease, the addition of
chemotherapy to radiation treatment has been explored.
Recent evidence suggests that concurrent chemotherapy
or chemotherapy post-radiation may be required in
high-risk, early-stage disease [8].
Due to the high reliance on radiotherapy for the treat-
ment of ENKTL, proper delineation of the target volume is
essential. MRI is often used for radiotherapy planning, but
it requires a cooperative patient and has several contraindi-
cations. A diagnostic MRI of the neck was contraindicated
in one our patients and was not tolerated in another.
Nonetheless, most patients are able to tolerate an MRI.
Even when MRI is possible, determining whether
there is lymph node involvement can be difficult. In
Figure 3 CT, MRI, and PET sagittal views. Patient was unable to tolerate the MRI, resulting in motion artefact.
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nodes were involved based on CT and MRI. Lymph
node size is often used to determine whether metastases
are present; however, lymph nodes can be enlarged as a
result of benign processes such as inflammation and
infection [12]. Conversely, small volume disease can be
present, but not visible on CT or MRI [12]. PET/CT
was more definitive in distinguishing malignant from
normal tissue in this case and changed the stage as well
as the treatment plan to involve irradiation of the nodes.
Few studies have examined the utility of PET/CT in
the management of ENKTL; however, the data that do
exist are promising. Most identified ENKTL lesions are
FDG-avid [9,13,14]. PET/CT results may be less reliable
for hepatic lesions and bone marrow involvement; Kar-
antanis et al. described ten patients, of which one with
ENKTL and one with NK-cell lineage lymphoprolifera-
tive disorder had hepatic metastases and bone marrow
involvement, respectively, that were not identified on
PET/CT [15].
Others have reported the utility of PET/CT in detect-
ing involved tissues not identified by CT and/or MRI
[9,16]. Berk et al. described how PET/CT detected
involved regional and distal lymph nodes not
Figure 4 CT, MRI, and PET axial views. Imaging shows the tumor involves the right nasal cavity and medial orbit.
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Page 6 of 8appreciated using CT in a patient with ENKTL [16] and
Kako et al. reported that out of eight patients, PET/CT
identified three involved areas not appreciated by con-
ventional methods. Unfortunately, the involved areas
were not defined in the Kako et al. paper [9].
Abnormal FDG uptake is typically defined as an
increase in background activity in surrounding tissue
that is unrelated to physiologic sites of uptake or excre-
tion [9,14,15]. One study has reported increased FDG
uptake in the soft palate (mean SUV 3.31), palatine ton-
sils (mean SUV 3.48), and lingual tonsils (mean SUV
3.11) of patients with no known head and neck
malignancy [17]. This finding suggests the possibility of
obtaining false-positive results when using PET/CT in
the head and neck area.
The incidence of false-positive results using PET/CT
in the management of ENKTL is unknown. Karantanis
et al. reported no false-positive results in their ten
patients. Kako et al. described one patient (out of eight)
with ENKTL that showed bone marrow involvement on
PET/CT that was negative on biopsy and aspiration [9].
In our patients, the areas deemed positive were inter-
preted by the reporting nuclear medicine physician as
abnormal and probably involved based on experience.
Figure 5 CT, MRI, and PET axial views. These enlarged lymph nodes were shown to be FDG-PET-avid, changing the stage from IAE to IIAE.
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or warranted for all lesions. However, since we did not
biopsy the tissues that were FDG-avid, but not appre-
ciated on CT and/or MRI, we cannot exclude the possi-
bility that the PET/CT results represented false-positive
results.
In all three cases, PET/CT improved target volume
delineation. We believe that PET/CT is a promising tool
that may be useful in the staging process and delinea-
tion of treatment target volumes in patients who will
receive radiotherapy for ENKTL. Further validation is
required in a larger cohort of patients.
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